MetaCap

Spero Therapeutics Inc. (SPRO)

NASDAQ: SPROHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.742-0.0843 (-10.20%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SPRO stock chart

Technical analysis

Key statistics

All statistics
Market cap
$43.23M
EPS (TTM)
-$0.50
52-week range
0.73 – 3.08
Day range
0.7301 – 0.81
Volume / Avg
424.81K / 530.46K
Beta
—

52-week range

$0.73$3.08

SPRO stock today

Shares of Spero Therapeutics (SPRO) finished lower on Nov 20 at $0.742, a drop of 10.20% or $0.0843 per share, versus the S&P 500's 3.70% decline. At this level, SPRO sits near the bottom of its 52-week range of $0.73 to $3.08: 75.9% below the high, set on May 27, 2026 and 1.6% above the low. SPRO is down 68.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 67.9%.

Spero Therapeutics has posted a net loss over the last twelve months (EPS of -$0.50), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Spero Therapeutics

Company profile

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Ms. Esther P. Rajavelu
Headquarters
Cambridge, MA
Employees
25
IPO year
2017

Financial highlights

Full financials

In fiscal 2025, Spero Therapeutics generated $66.8 million in revenue, up 39.2% from fiscal 2024. Net income was $8.6 million, for a net margin of 12.8% versus a median of -142.9% in the prior 5 years. Operating margin was 9.5%.

Spero Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$66.80M$47.98M$103.78M$53.51M$18.26M
Growth+39.24%-53.77%+93.95%+193.10%+95.67%
Net income$8.57M$-68.57M$22.81M$-46.41M$-89.80M
EPS (diluted)$0.15$-1.27$0.43$-1.23$-2.91

Analyst forecast

Forecast

Consensus (2 analysts)

none

Avg. price target

$5.00+573.85%

  • Strong buy 0
  • Buy 1
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $4.00High $6.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.76 vs $-0.14
Surprise
-442.86%

SPRO news

All SPRO news

Spero Therapeutics peers

Health Care sector
SPRO peer companies
CompanyPrice% ChgMarket capCompare
RLYBRallybio Corporation15.47-0.32%$43.32Mvs SPRO
CRBPCorbus Pharmaceuticals Holdings Inc.2.06-15.40%$42.45Mvs SPRO
ANVSAnnovis Bio Inc.0.7113-4.96%$44.12Mvs SPRO
INCRIntercure Ltd.3.24-7.69%$42.03Mvs SPRO
OSTXOS Therapies Incorporated0.803-2.12%$42.00Mvs SPRO
GANXGain Therapeutics Inc.0.9994-4.82%$44.50Mvs SPRO
QUCYQuantum Cyber N.V.0.512-7.25%$44.67Mvs SPRO
BMEABiomea Fusion Inc.0.5744-2.38%$41.75Mvs SPRO

Indexes, lists and sector

Spero Therapeutics stock FAQ

What is Spero Therapeutics's stock price today?

SPRO last traded at $0.742 as of Nov 20, 4:00 PM EST, down 10.20% on the day. Prices are delayed at least 15 minutes.

Who is Spero Therapeutics's CEO?

Ms. Esther P. Rajavelu is the chief executive officer of Spero Therapeutics Inc., which has about 25 employees.

What is the SPRO 52-week high?

The 52-week high for SPRO is $3.08 and the 52-week low is $0.73. The stock is currently 75.9% below its high.

Compare SPRO